Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Icahn Renews Effort To Replace Visx Board At Next Shareholder Meeting

This article was originally published in The Gray Sheet

Executive Summary

Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed

You may also be interested in...



Visx

Financier Carl Icahn declares intent to nominate Keith Meister to the ophthalmic firm's board of directors. Icahn, who owns 11.6% of the company, had scrapped plans to elect a rival slate of directors in March. A hostile takeover was initially proposed in April 2001 (1"The Gray Sheet" Nov. 26, 2001, p. 30)...

Visx

Financier Carl Icahn declares intent to nominate Keith Meister to the ophthalmic firm's board of directors. Icahn, who owns 11.6% of the company, had scrapped plans to elect a rival slate of directors in March. A hostile takeover was initially proposed in April 2001 (1"The Gray Sheet" Nov. 26, 2001, p. 30)...

Visx

Financier Carl Icahn forgoes earlier plan to elect a rival slate of directors to the firm's board at the May 2002 annual meeting (1"The Gray Sheet" Nov. 26, 2001, p. 30). In a recent 13D filing with the Securities & Exchange Commission, Icahn maintained that depending upon market conditions, he may acquire or dispose of additional shares. Icahn previously proposed to acquire Visx for $32 per share in a hostile takeover bid last April...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel